CAS No.
96684-39-8
Chemical Name:
piroxicam-beta-cyclodextrin
Synonyms
PBCD;Chf-1194;Chf 1194;Cycladol;PubChem ID: 54697648;Piroxicam-β-Cyclodex;Piroxicam-β-cyclodextrin;(3E)-3-[hydroxy(pyridin-2-ylam;Piroxicambeta-Cyclodextrin(x:1);PiroxicaM-β-cyclodextrin coMplex
CBNumber:
CB21317417
Molecular Formula:
C57H83N3O39S
Molecular Weight:
1466.33
MDL Number:
MFCD09952585
MOL File:
96684-39-8.mol
*The following content is generated by AI and is for reference only.
Piroxicam-β-cyclodextrin is a sophisticated pharmaceutical complex formed by the non-covalent inclusion of piroxicam, a potent non-steroidal anti-inflammatory drug (NSAID), within the hydrophobic cavity of β-cyclodextrin. This formulation significantly enhances the physicochemical properties of the parent drug, addressing critical limitations such as poor aqueous solubility and variable bioavailability often associated with piroxicam in its crystalline form. The molecular formula of the resulting complex is typically represented as C15H13N3O4S·C42H70O35, reflecting the stoichiometric association between the active ingredient and the cyclodextrin host molecule, although exact ratios can vary based on preparation methods. While piroxicam itself carries a CAS number of 36322-90-6, the specific complex does not always possess a unique, universally registered CAS number distinct from its components, as it is often classified under the broader category of drug-excipient systems rather than a single chemical entity.
The primary application of Piroxicam-β-cyclodextrin lies in the management of inflammatory conditions, including rheumatoid arthritis, osteoarthritis, and acute musculoskeletal disorders. By improving the dissolution rate and stability of piroxicam, this complex facilitates more consistent absorption in the gastrointestinal tract, potentially reducing the required dosage and minimizing local gastric irritation, a common side effect of traditional NSAID therapy. The inclusion technology also offers advantages in solid dosage forms like tablets and capsules, ensuring better flowability and compressibility during manufacturing. Furthermore, the enhanced stability protects the drug from degradation caused by light or moisture, extending shelf life. This advanced delivery system represents a strategic approach in modern pharmaceutics to optimize therapeutic efficacy while improving patient compliance through reduced dosing frequency and fewer adverse effects. Consequently, Piroxicam-β-cyclodextrin serves as a vital tool for clinicians seeking effective pain relief and inflammation control with an improved safety profile compared to conventional formulations.